{"transactions":[{"id":2769844,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option","published_at":"2021-03-29T10:12:25.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":3504,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":3504,"derivative":{"exercise_price":117.43,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":3504},"source":{"system":"sec-edgar","filing":"0001209191-21-023372","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121023372/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-09"}},{"id":2872972,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Restricted Stock Unit","published_at":"2021-02-10T02:27:51.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":532,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025."}],"balance_after":532,"derivative":{"underlying":"Common Stock","underlying_shares":532},"source":{"system":"sec-edgar","filing":"0001209191-21-009130","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009130/doc4.xml","form_type":"4"}},{"id":2872971,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option","published_at":"2021-02-10T02:27:51.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":3188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter."}],"balance_after":3188,"derivative":{"exercise_price":117.63,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":3188},"source":{"system":"sec-edgar","filing":"0001209191-21-009130","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009130/doc4.xml","form_type":"4"}},{"id":2872970,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:27:51.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":1623,"price":116.7902,"value":189550.4946,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.99 to $117.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":157651,"source":{"system":"sec-edgar","filing":"0001209191-21-009130","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009130/doc4.xml","form_type":"4"}},{"id":2872969,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:27:51.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":1395,"price":116.783,"value":162912.285,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 1,395 shares of common stock issued upon vesting of 2,650 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,255) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.90 to $117.84. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":156189,"source":{"system":"sec-edgar","filing":"0001209191-21-009130","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009130/doc4.xml","form_type":"4"}},{"id":2872968,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:27:51.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":824,"price":116.8517,"value":96285.8008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 824 shares of common stock issued upon vesting of 2,430 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,606) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.97 to $117.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":154934,"source":{"system":"sec-edgar","filing":"0001209191-21-009130","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009130/doc4.xml","form_type":"4"}},{"id":2872967,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2021-02-10T02:27:51.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":704,"price":113.7905,"value":80108.512,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 704 shares of common stock issued upon vesting of 1,338 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (634) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.66 to $116.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":153328,"source":{"system":"sec-edgar","filing":"0001209191-21-009130","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919121009130/doc4.xml","form_type":"4"}},{"id":2980244,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-11-16T23:08:41.000Z","date":"2020-11-12","kind":"sale","acquired":false,"shares":2257,"price":90.7428,"value":204806.4996,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,257 shares of common stock issued upon vesting of 4,288 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,031) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $88.93 to $92.23. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":152694,"source":{"system":"sec-edgar","filing":"0001209191-20-058539","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120058539/doc4.xml","form_type":"4"}},{"id":3065171,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-08-07T23:14:49.000Z","date":"2020-08-05","kind":"sale","acquired":false,"shares":2257,"price":118.8854,"value":268324.3478,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 2,257 shares of common stock issued upon vesting of 4,287 performance restricted stock units to cover withholding\ntaxes, with the balance of the shares (2,030) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a\nbroker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction\ndate in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan\nsubsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.34 to $120.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":150663,"source":{"system":"sec-edgar","filing":"0001209191-20-045742","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120045742/doc4.xml","form_type":"4"}},{"id":3149599,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2020-05-15T00:09:50.000Z","date":"2020-05-12","kind":"exercise","acquired":false,"shares":18057,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Option granted February 07, 2019 and vests monthly over four years."}],"balance_after":47383,"derivative":{"exercise_price":81.05,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":18057},"source":{"system":"sec-edgar","filing":"0001209191-20-029401","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120029401/doc4.xml","form_type":"4"}},{"id":3149598,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2020-05-15T00:09:50.000Z","date":"2020-05-12","kind":"exercise","acquired":false,"shares":15833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Option granted February 05, 2018 and vests monthly over four years."}],"balance_after":13340,"derivative":{"exercise_price":81.49,"expiration_date":"2028-02-05","underlying":"Common Stock","underlying_shares":15833},"source":{"system":"sec-edgar","filing":"0001209191-20-029401","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120029401/doc4.xml","form_type":"4"}},{"id":3149597,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2020-05-15T00:09:50.000Z","date":"2020-05-12","kind":"exercise","acquired":false,"shares":18571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 06, 2017 and vests monthly over four years."}],"balance_after":15289,"derivative":{"exercise_price":43.24,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":18571},"source":{"system":"sec-edgar","filing":"0001209191-20-029401","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120029401/doc4.xml","form_type":"4"}},{"id":3149596,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2020-05-15T00:09:50.000Z","date":"2020-05-12","kind":"exercise","acquired":false,"shares":9094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted February 05, 2016 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":9094},"source":{"system":"sec-edgar","filing":"0001209191-20-029401","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120029401/doc4.xml","form_type":"4"}},{"id":3149595,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-05-15T00:09:50.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":18057,"price":114.9443,"value":2075549.2251,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.43 to $117.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":148633,"source":{"system":"sec-edgar","filing":"0001209191-20-029401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120029401/doc4.xml","form_type":"4"}},{"id":3149594,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-05-15T00:09:50.000Z","date":"2020-05-12","kind":"exercise","acquired":true,"shares":18057,"price":81.05,"value":1463519.85,"ownership":{"direct":true},"balance_after":166690,"source":{"system":"sec-edgar","filing":"0001209191-20-029401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120029401/doc4.xml","form_type":"4"}},{"id":3149593,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-05-15T00:09:50.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":15833,"price":114.9443,"value":1819913.1019,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.43 to $117.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":148633,"source":{"system":"sec-edgar","filing":"0001209191-20-029401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120029401/doc4.xml","form_type":"4"}},{"id":3149592,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-05-15T00:09:50.000Z","date":"2020-05-12","kind":"exercise","acquired":true,"shares":15833,"price":81.49,"value":1290231.17,"ownership":{"direct":true},"balance_after":164466,"source":{"system":"sec-edgar","filing":"0001209191-20-029401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120029401/doc4.xml","form_type":"4"}},{"id":3149591,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-05-15T00:09:50.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":18571,"price":114.9443,"value":2134630.5953,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.43 to $117.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":148633,"source":{"system":"sec-edgar","filing":"0001209191-20-029401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120029401/doc4.xml","form_type":"4"}},{"id":3149590,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-05-15T00:09:50.000Z","date":"2020-05-12","kind":"exercise","acquired":true,"shares":18571,"price":43.24,"value":803010.04,"ownership":{"direct":true},"balance_after":167204,"source":{"system":"sec-edgar","filing":"0001209191-20-029401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120029401/doc4.xml","form_type":"4"}},{"id":3149589,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-05-15T00:09:50.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":9094,"price":114.9443,"value":1045303.4642,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.43 to $117.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":148633,"source":{"system":"sec-edgar","filing":"0001209191-20-029401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120029401/doc4.xml","form_type":"4"}},{"id":3149588,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-05-15T00:09:50.000Z","date":"2020-05-12","kind":"exercise","acquired":true,"shares":9094,"price":35.99,"value":327293.06,"ownership":{"direct":true},"balance_after":157727,"source":{"system":"sec-edgar","filing":"0001209191-20-029401","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120029401/doc4.xml","form_type":"4"}},{"id":3168573,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-04-29T00:35:36.000Z","date":"2020-04-24","kind":"sale","acquired":false,"shares":1934,"price":99.4577,"value":192351.1918,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.65 to $101.11. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 251 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020."}],"balance_after":148633,"source":{"system":"sec-edgar","filing":"0001209191-20-026064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120026064/doc4.xml","form_type":"4"}},{"id":3280424,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-02-12T00:09:42.000Z","date":"2020-02-07","kind":"sale","acquired":false,"shares":1623,"price":103.3282,"value":167701.6686,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,623 shares of common stock issued upon vesting of 3,084 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,461) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.23 to $104.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":146641,"source":{"system":"sec-edgar","filing":"0001209191-20-008484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120008484/doc4.xml","form_type":"4"}},{"id":3285269,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Restricted Stock Unit","published_at":"2020-02-07T23:37:35.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":2430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The Restricted Stock Units vests in full on February 6, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The Restricted Stock Units vests in full on February 6, 2021."}],"balance_after":2430,"derivative":{"underlying":"Common Stock","underlying_shares":2430},"source":{"system":"sec-edgar","filing":"0001209191-20-007674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007674/doc4.xml","form_type":"4"}},{"id":3285268,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option","published_at":"2020-02-07T23:37:35.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":15337,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Represents option which vests in full on February 6, 2021."}],"balance_after":15337,"derivative":{"exercise_price":102.9,"exercise_date":"2021-02-06","expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":15337},"source":{"system":"sec-edgar","filing":"0001209191-20-007674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007674/doc4.xml","form_type":"4"}},{"id":3285267,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-02-07T23:37:35.000Z","date":"2020-02-06","kind":"sale","acquired":false,"shares":1395,"price":101.5556,"value":141670.062,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Sale of 1,395 shares of common stock issued upon vesting of 2,650 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,255) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.12 to $103.08. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":145180,"source":{"system":"sec-edgar","filing":"0001209191-20-007674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007674/doc4.xml","form_type":"4"}},{"id":3285266,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-02-07T23:37:35.000Z","date":"2020-02-05","kind":"sale","acquired":false,"shares":704,"price":103.0623,"value":72555.8592,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Sale of 704 shares of common stock issued upon vesting of 1,337 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (633) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $104.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":143925,"source":{"system":"sec-edgar","filing":"0001209191-20-007674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007674/doc4.xml","form_type":"4"}},{"id":3285265,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2020-02-07T23:37:35.000Z","date":"2020-02-05","kind":"sale","acquired":false,"shares":1342,"price":102.9978,"value":138223.0476,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,342 shares of common stock issued upon vesting of 2,550 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,208) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.85 to $105.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes a total of 108 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on August 30, 2019."}],"balance_after":143292,"source":{"system":"sec-edgar","filing":"0001209191-20-007674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919120007674/doc4.xml","form_type":"4"}},{"id":3452570,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-07-31T23:11:19.000Z","date":"2019-07-30","kind":"exercise","acquired":false,"shares":25600,"price":43.24,"value":1106944.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Option granted February 6, 2017 and vests monthly over four years."}],"balance_after":33860,"derivative":{"exercise_price":43.24,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":25600},"source":{"system":"sec-edgar","filing":"0001209191-19-043914","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119043914/doc4.xml","form_type":"4"}},{"id":3452569,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-07-31T23:11:19.000Z","date":"2019-07-30","kind":"exercise","acquired":false,"shares":18756,"price":32.99,"value":618760.44,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 3, 2015 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":18756},"source":{"system":"sec-edgar","filing":"0001209191-19-043914","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119043914/doc4.xml","form_type":"4"}},{"id":3452568,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-07-31T23:11:19.000Z","date":"2019-07-30","kind":"sale","acquired":false,"shares":25600,"price":93.5245,"value":2394227.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $91.77 to $94.82. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-043914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119043914/doc4.xml","form_type":"4"}},{"id":3452567,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-07-31T23:11:19.000Z","date":"2019-07-30","kind":"exercise","acquired":true,"shares":25600,"price":43.24,"value":1106944.0,"ownership":{"direct":true},"balance_after":167576,"source":{"system":"sec-edgar","filing":"0001209191-19-043914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119043914/doc4.xml","form_type":"4"}},{"id":3452566,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-07-31T23:11:19.000Z","date":"2019-07-30","kind":"sale","acquired":false,"shares":18756,"price":91.7376,"value":1720630.4256,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $91.66 to $91.77. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-043914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119043914/doc4.xml","form_type":"4"}},{"id":3452565,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-07-31T23:11:19.000Z","date":"2019-07-30","kind":"exercise","acquired":true,"shares":18756,"price":32.99,"value":618760.44,"ownership":{"direct":true},"balance_after":160732,"source":{"system":"sec-edgar","filing":"0001209191-19-043914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119043914/doc4.xml","form_type":"4"}},{"id":3460292,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-07-17T23:08:52.000Z","date":"2019-07-15","kind":"exercise","acquired":false,"shares":30680,"price":32.99,"value":1012133.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted February 3, 2015 and vested monthly over four years."}],"balance_after":18756,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":30680},"source":{"system":"sec-edgar","filing":"0001209191-19-042522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119042522/doc4.xml","form_type":"4"}},{"id":3460291,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-07-17T23:08:52.000Z","date":"2019-07-15","kind":"sale","acquired":false,"shares":30680,"price":87.5002,"value":2684506.136,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $86.08 to $88.38. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-042522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119042522/doc4.xml","form_type":"4"}},{"id":3460290,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-07-17T23:08:52.000Z","date":"2019-07-15","kind":"exercise","acquired":true,"shares":30680,"price":32.99,"value":1012133.2,"ownership":{"direct":true},"balance_after":172656,"source":{"system":"sec-edgar","filing":"0001209191-19-042522","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119042522/doc4.xml","form_type":"4"}},{"id":3463207,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-07-12T20:15:18.000Z","date":"2019-07-11","kind":"exercise","acquired":false,"shares":100,"price":32.99,"value":3299.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted February 3, 2015 and vested monthly over four years."}],"balance_after":49436,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0001209191-19-041925","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119041925/doc4.xml","form_type":"4"}},{"id":3463206,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-07-12T20:15:18.000Z","date":"2019-07-10","kind":"exercise","acquired":false,"shares":7120,"price":32.99,"value":234888.8,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted February 3, 2015 and vested monthly over four years."}],"balance_after":49536,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":7120},"source":{"system":"sec-edgar","filing":"0001209191-19-041925","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119041925/doc4.xml","form_type":"4"}},{"id":3463205,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-07-12T20:15:18.000Z","date":"2019-07-11","kind":"sale","acquired":false,"shares":100,"price":87.59,"value":8759.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-041925","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119041925/doc4.xml","form_type":"4"}},{"id":3463204,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-07-12T20:15:18.000Z","date":"2019-07-11","kind":"exercise","acquired":true,"shares":100,"price":32.99,"value":3299.0,"ownership":{"direct":true},"balance_after":142076,"source":{"system":"sec-edgar","filing":"0001209191-19-041925","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119041925/doc4.xml","form_type":"4"}},{"id":3463203,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-07-12T20:15:18.000Z","date":"2019-07-10","kind":"sale","acquired":false,"shares":7120,"price":87.6345,"value":623957.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.50 to $87.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-041925","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119041925/doc4.xml","form_type":"4"}},{"id":3463202,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-07-12T20:15:18.000Z","date":"2019-07-10","kind":"exercise","acquired":true,"shares":7120,"price":32.99,"value":234888.8,"ownership":{"direct":true},"balance_after":149096,"source":{"system":"sec-edgar","filing":"0001209191-19-041925","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119041925/doc4.xml","form_type":"4"}},{"id":3483183,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-06-20T21:56:30.000Z","date":"2019-06-18","kind":"exercise","acquired":false,"shares":2100,"price":32.99,"value":69279.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted February 3, 2015 and vested monthly over four years."}],"balance_after":56656,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":2100},"source":{"system":"sec-edgar","filing":"0001209191-19-038288","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119038288/doc4.xml","form_type":"4"}},{"id":3483182,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-06-20T21:56:30.000Z","date":"2019-06-18","kind":"sale","acquired":false,"shares":2100,"price":87.8174,"value":184416.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.53 to $87.965. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-038288","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119038288/doc4.xml","form_type":"4"}},{"id":3483181,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-06-20T21:56:30.000Z","date":"2019-06-18","kind":"exercise","acquired":true,"shares":2100,"price":32.99,"value":69279.0,"ownership":{"direct":true},"balance_after":144076,"source":{"system":"sec-edgar","filing":"0001209191-19-038288","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119038288/doc4.xml","form_type":"4"}},{"id":3488507,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-06-17T21:47:52.000Z","date":"2019-06-13","kind":"exercise","acquired":false,"shares":1432,"price":32.99,"value":47241.68,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Option granted February 3, 2015 and vested monthly over four years."}],"balance_after":58756,"derivative":{"exercise_price":32.99,"expiration_date":"2025-02-03","underlying":"Common Stock","underlying_shares":1432},"source":{"system":"sec-edgar","filing":"0001209191-19-037472","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119037472/doc4.xml","form_type":"4"}},{"id":3488506,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-06-17T21:47:52.000Z","date":"2019-06-13","kind":"exercise","acquired":false,"shares":15836,"price":19.59,"value":310227.24,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted January 16, 2014 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":19.59,"expiration_date":"2024-01-16","underlying":"Common Stock","underlying_shares":15836},"source":{"system":"sec-edgar","filing":"0001209191-19-037472","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119037472/doc4.xml","form_type":"4"}},{"id":3488505,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-06-17T21:47:52.000Z","date":"2019-06-13","kind":"sale","acquired":false,"shares":1432,"price":83.2898,"value":119270.9936,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $83.18 to $83.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-037472","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119037472/doc4.xml","form_type":"4"}},{"id":3488504,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-06-17T21:47:52.000Z","date":"2019-06-13","kind":"exercise","acquired":true,"shares":1432,"price":32.99,"value":47241.68,"ownership":{"direct":true},"balance_after":143408,"source":{"system":"sec-edgar","filing":"0001209191-19-037472","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119037472/doc4.xml","form_type":"4"}},{"id":3488503,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-06-17T21:47:52.000Z","date":"2019-06-13","kind":"sale","acquired":false,"shares":15836,"price":82.556,"value":1307356.816,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.63 to $83.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-037472","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119037472/doc4.xml","form_type":"4"}},{"id":3488502,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-06-17T21:47:52.000Z","date":"2019-06-13","kind":"exercise","acquired":true,"shares":15836,"price":19.59,"value":310227.24,"ownership":{"direct":true},"balance_after":157812,"source":{"system":"sec-edgar","filing":"0001209191-19-037472","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119037472/doc4.xml","form_type":"4"}},{"id":3501216,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-06-05T22:26:23.000Z","date":"2019-06-03","kind":"exercise","acquired":false,"shares":3435,"price":19.59,"value":67291.65,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted January 16, 2014 and vested monthly over four years."}],"balance_after":15836,"derivative":{"exercise_price":19.59,"expiration_date":"2024-01-16","underlying":"Common Stock","underlying_shares":3435},"source":{"system":"sec-edgar","filing":"0001209191-19-034913","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119034913/doc4.xml","form_type":"4"}},{"id":3501215,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-06-05T22:26:23.000Z","date":"2019-06-03","kind":"sale","acquired":false,"shares":3435,"price":85.5076,"value":293718.606,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.74. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-034913","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119034913/doc4.xml","form_type":"4"}},{"id":3501214,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-06-05T22:26:23.000Z","date":"2019-06-03","kind":"exercise","acquired":true,"shares":3435,"price":19.59,"value":67291.65,"ownership":{"direct":true},"balance_after":145411,"source":{"system":"sec-edgar","filing":"0001209191-19-034913","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119034913/doc4.xml","form_type":"4"}},{"id":3505507,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-06-03T22:18:25.000Z","date":"2019-05-31","kind":"exercise","acquired":false,"shares":19297,"price":19.59,"value":378028.23,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted January 16, 2014 and vested monthly over four years."}],"balance_after":19271,"derivative":{"exercise_price":19.59,"expiration_date":"2024-01-16","underlying":"Common Stock","underlying_shares":19297},"source":{"system":"sec-edgar","filing":"0001209191-19-034056","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119034056/doc4.xml","form_type":"4"}},{"id":3505506,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-06-03T22:18:25.000Z","date":"2019-05-31","kind":"sale","acquired":false,"shares":19297,"price":85.0174,"value":1640580.7678,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.17. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-034056","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119034056/doc4.xml","form_type":"4"}},{"id":3505505,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-06-03T22:18:25.000Z","date":"2019-05-31","kind":"exercise","acquired":true,"shares":19297,"price":19.59,"value":378028.23,"ownership":{"direct":true},"balance_after":161273,"source":{"system":"sec-edgar","filing":"0001209191-19-034056","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119034056/doc4.xml","form_type":"4"}},{"id":3509274,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-05-29T21:45:35.000Z","date":"2019-05-24","kind":"exercise","acquired":false,"shares":17486,"price":19.59,"value":342550.74,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted January 16, 2014 and vested monthly over four years."}],"balance_after":38568,"derivative":{"exercise_price":19.59,"expiration_date":"2024-01-16","underlying":"Common Stock","underlying_shares":17486},"source":{"system":"sec-edgar","filing":"0001209191-19-033260","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119033260/doc4.xml","form_type":"4"}},{"id":3509273,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-05-29T21:45:35.000Z","date":"2019-05-24","kind":"sale","acquired":false,"shares":17486,"price":80.0317,"value":1399434.3062,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.16. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-033260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119033260/doc4.xml","form_type":"4"}},{"id":3509272,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-05-29T21:45:35.000Z","date":"2019-05-24","kind":"exercise","acquired":true,"shares":17486,"price":19.59,"value":342550.74,"ownership":{"direct":true},"balance_after":159462,"source":{"system":"sec-edgar","filing":"0001209191-19-033260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119033260/doc4.xml","form_type":"4"}},{"id":3514012,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-05-23T22:27:24.000Z","date":"2019-05-22","kind":"exercise","acquired":false,"shares":1300,"price":19.59,"value":25467.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted January 16, 2014 and vested monthly over four years."}],"balance_after":56054,"derivative":{"exercise_price":19.59,"expiration_date":"2024-01-16","underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0001209191-19-032451","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119032451/doc4.xml","form_type":"4"}},{"id":3514011,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-05-23T22:27:24.000Z","date":"2019-05-22","kind":"sale","acquired":false,"shares":1300,"price":80.0285,"value":104037.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-032451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119032451/doc4.xml","form_type":"4"}},{"id":3514010,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-05-23T22:27:24.000Z","date":"2019-05-22","kind":"exercise","acquired":true,"shares":1300,"price":19.59,"value":25467.0,"ownership":{"direct":true},"balance_after":143276,"source":{"system":"sec-edgar","filing":"0001209191-19-032451","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119032451/doc4.xml","form_type":"4"}},{"id":3519317,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-05-20T22:36:31.000Z","date":"2019-05-16","kind":"exercise","acquired":false,"shares":731,"price":19.59,"value":14320.29,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Option granted January 16, 2014 and vested monthly over four years."}],"balance_after":57354,"derivative":{"exercise_price":19.59,"expiration_date":"2024-01-16","underlying":"Common Stock","underlying_shares":731},"source":{"system":"sec-edgar","filing":"0001209191-19-031531","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119031531/doc4.xml","form_type":"4"}},{"id":3519316,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-05-20T22:36:31.000Z","date":"2019-05-16","kind":"exercise","acquired":false,"shares":34376,"price":8.65,"value":297352.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Option granted January 10, 2013 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":8.65,"expiration_date":"2023-01-10","underlying":"Common Stock","underlying_shares":34376},"source":{"system":"sec-edgar","filing":"0001209191-19-031531","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119031531/doc4.xml","form_type":"4"}},{"id":3519315,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-05-20T22:36:31.000Z","date":"2019-05-16","kind":"exercise","acquired":false,"shares":9121,"price":5.76,"value":52536.96,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted August 25, 2011 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":5.76,"expiration_date":"2021-08-25","underlying":"Common Stock","underlying_shares":9121},"source":{"system":"sec-edgar","filing":"0001209191-19-031531","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119031531/doc4.xml","form_type":"4"}},{"id":3519314,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-05-20T22:36:31.000Z","date":"2019-05-16","kind":"exercise","acquired":false,"shares":22439,"price":35.99,"value":807579.61,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted February 05, 2016 and vests monthly over four years."}],"balance_after":9094,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":22439},"source":{"system":"sec-edgar","filing":"0001209191-19-031531","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119031531/doc4.xml","form_type":"4"}},{"id":3519313,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-05-20T22:36:31.000Z","date":"2019-05-16","kind":"sale","acquired":false,"shares":731,"price":80.128,"value":58573.568,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-031531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119031531/doc4.xml","form_type":"4"}},{"id":3519312,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-05-20T22:36:31.000Z","date":"2019-05-16","kind":"exercise","acquired":true,"shares":731,"price":19.59,"value":14320.29,"ownership":{"direct":true},"balance_after":142707,"source":{"system":"sec-edgar","filing":"0001209191-19-031531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119031531/doc4.xml","form_type":"4"}},{"id":3519311,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-05-20T22:36:31.000Z","date":"2019-05-16","kind":"sale","acquired":false,"shares":34376,"price":80.128,"value":2754480.128,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-031531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119031531/doc4.xml","form_type":"4"}},{"id":3519310,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-05-20T22:36:31.000Z","date":"2019-05-16","kind":"exercise","acquired":true,"shares":34376,"price":8.65,"value":297352.4,"ownership":{"direct":true},"balance_after":176352,"source":{"system":"sec-edgar","filing":"0001209191-19-031531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119031531/doc4.xml","form_type":"4"}},{"id":3519309,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-05-20T22:36:31.000Z","date":"2019-05-16","kind":"sale","acquired":false,"shares":9121,"price":80.128,"value":730847.488,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-031531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119031531/doc4.xml","form_type":"4"}},{"id":3519308,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-05-20T22:36:31.000Z","date":"2019-05-16","kind":"exercise","acquired":true,"shares":9121,"price":5.76,"value":52536.96,"ownership":{"direct":true},"balance_after":151097,"source":{"system":"sec-edgar","filing":"0001209191-19-031531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119031531/doc4.xml","form_type":"4"}},{"id":3519307,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-05-20T22:36:31.000Z","date":"2019-05-16","kind":"sale","acquired":false,"shares":22439,"price":80.128,"value":1797992.192,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-031531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119031531/doc4.xml","form_type":"4"}},{"id":3519306,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-05-20T22:36:31.000Z","date":"2019-05-16","kind":"exercise","acquired":true,"shares":22439,"price":35.99,"value":807579.61,"ownership":{"direct":true},"balance_after":164415,"source":{"system":"sec-edgar","filing":"0001209191-19-031531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119031531/doc4.xml","form_type":"4"}},{"id":3526616,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2019-05-15T23:23:35.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":34547,"price":8.66,"value":299177.02,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted January 12, 2012 and vested monthly over four years."}],"balance_after":0,"derivative":{"exercise_price":8.66,"expiration_date":"2022-01-12","underlying":"Common Stock","underlying_shares":34547},"source":{"system":"sec-edgar","filing":"0001209191-19-030172","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119030172/doc4.xml","form_type":"4"}},{"id":3526615,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-05-15T23:23:35.000Z","date":"2019-05-13","kind":"sale","acquired":false,"shares":34547,"price":75.5149,"value":2608813.2503,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $74.26 to $77.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141976,"source":{"system":"sec-edgar","filing":"0001209191-19-030172","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119030172/doc4.xml","form_type":"4"}},{"id":3526614,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-05-15T23:23:35.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":34547,"price":8.66,"value":299177.02,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 337 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2019."}],"balance_after":176523,"source":{"system":"sec-edgar","filing":"0001209191-19-030172","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119030172/doc4.xml","form_type":"4"}},{"id":3669075,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Restricted Stock Unit","published_at":"2019-02-08T22:06:51.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":12339,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023."}],"balance_after":12339,"derivative":{"underlying":"Common Stock","underlying_shares":12339},"source":{"system":"sec-edgar","filing":"0001209191-19-008629","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119008629/doc4.xml","form_type":"4"}},{"id":3669074,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option","published_at":"2019-02-08T22:06:51.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":66673,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter."}],"balance_after":66673,"derivative":{"exercise_price":81.05,"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":66673},"source":{"system":"sec-edgar","filing":"0001209191-19-008629","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119008629/doc4.xml","form_type":"4"}},{"id":3669073,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-02-08T22:06:51.000Z","date":"2019-02-06","kind":"sale","acquired":false,"shares":920,"price":83.5428,"value":76859.376,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 920 shares of common stock issued upon vesting of 2,650 restricted stock units on February 6, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,730) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.78 to $84.9950. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":141639,"source":{"system":"sec-edgar","filing":"0001209191-19-008629","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119008629/doc4.xml","form_type":"4"}},{"id":3672749,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-02-06T22:59:34.000Z","date":"2019-02-05","kind":"sale","acquired":false,"shares":885,"price":88.1775,"value":78037.0875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Sale of 885 shares of common stock issued upon vesting of 2,550 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,665) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.48 to $88.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":139909,"source":{"system":"sec-edgar","filing":"0001209191-19-007847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119007847/doc4.xml","form_type":"4"}},{"id":3672748,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-02-06T22:59:34.000Z","date":"2019-02-05","kind":"sale","acquired":false,"shares":465,"price":88.0631,"value":40949.3415,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Sale of 465 shares of common stock issued upon vesting of 1,337 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (872) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.53 to $88.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":138244,"source":{"system":"sec-edgar","filing":"0001209191-19-007847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119007847/doc4.xml","form_type":"4"}},{"id":3672747,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-02-06T22:59:34.000Z","date":"2019-02-04","kind":"sale","acquired":false,"shares":1375,"price":88.1011,"value":121139.0125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,375 shares of common stock issued upon vesting of 2,750 restricted stock units on February 4, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,375) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.72 to $88.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":137372,"source":{"system":"sec-edgar","filing":"0001209191-19-007847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919119007847/doc4.xml","form_type":"4"}},{"id":3768517,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-11-13T21:15:40.000Z","date":"2018-11-08","kind":"exercise","acquired":true,"shares":16794,"price":8.65,"value":145268.1,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option granted January 10, 2013 and vested monthly over four years."}],"balance_after":34376,"derivative":{"exercise_price":8.65,"expiration_date":"2023-01-10","underlying":"Common Stock","underlying_shares":16794},"source":{"system":"sec-edgar","filing":"0001209191-18-058222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118058222/doc4.xml","form_type":"4"}},{"id":3768516,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-11-13T21:15:40.000Z","date":"2018-11-08","kind":"exercise","acquired":true,"shares":19501,"price":8.66,"value":168878.66,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option granted January 12, 2012 and vested monthly over four years."}],"balance_after":34547,"derivative":{"exercise_price":8.66,"expiration_date":"2022-01-12","underlying":"Common Stock","underlying_shares":19501},"source":{"system":"sec-edgar","filing":"0001209191-18-058222","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118058222/doc4.xml","form_type":"4"}},{"id":3768515,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2018-11-13T21:15:40.000Z","date":"2018-11-08","kind":"sale","acquired":false,"shares":16794,"price":110,"value":1847340.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":135997,"source":{"system":"sec-edgar","filing":"0001209191-18-058222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118058222/doc4.xml","form_type":"4"}},{"id":3768514,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2018-11-13T21:15:40.000Z","date":"2018-11-08","kind":"exercise","acquired":true,"shares":16794,"price":8.65,"value":145268.1,"ownership":{"direct":true},"balance_after":152791,"source":{"system":"sec-edgar","filing":"0001209191-18-058222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118058222/doc4.xml","form_type":"4"}},{"id":3768513,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2018-11-13T21:15:40.000Z","date":"2018-11-08","kind":"sale","acquired":false,"shares":19501,"price":110,"value":2145110.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":135997,"source":{"system":"sec-edgar","filing":"0001209191-18-058222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118058222/doc4.xml","form_type":"4"}},{"id":3768512,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2018-11-13T21:15:40.000Z","date":"2018-11-08","kind":"exercise","acquired":true,"shares":19501,"price":8.66,"value":168878.66,"ownership":{"direct":true},"balance_after":155498,"source":{"system":"sec-edgar","filing":"0001209191-18-058222","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118058222/doc4.xml","form_type":"4"}},{"id":3770920,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-11-08T22:04:06.000Z","date":"2018-11-07","kind":"exercise","acquired":true,"shares":15046,"price":8.66,"value":130298.36,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Option granted January 12, 2012 and vested monthly over four years."}],"balance_after":54048,"derivative":{"exercise_price":8.66,"expiration_date":"2022-01-12","underlying":"Common Stock","underlying_shares":15046},"source":{"system":"sec-edgar","filing":"0001209191-18-057772","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057772/doc4.xml","form_type":"4"}},{"id":3770919,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-11-08T22:04:06.000Z","date":"2018-11-07","kind":"exercise","acquired":true,"shares":9122,"price":5.76,"value":52542.72,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Option granted August 25, 2011 and vested monthly over four years."}],"balance_after":9121,"derivative":{"exercise_price":5.76,"expiration_date":"2021-08-25","underlying":"Common Stock","underlying_shares":9122},"source":{"system":"sec-edgar","filing":"0001209191-18-057772","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057772/doc4.xml","form_type":"4"}},{"id":3770918,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-11-08T22:04:06.000Z","date":"2018-11-07","kind":"exercise","acquired":true,"shares":5231,"price":35.99,"value":188263.69,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 05, 2016 and vested monthly over four years."}],"balance_after":31533,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":5231},"source":{"system":"sec-edgar","filing":"0001209191-18-057772","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057772/doc4.xml","form_type":"4"}},{"id":3770917,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-11-08T22:04:06.000Z","date":"2018-11-06","kind":"exercise","acquired":true,"shares":9420,"price":35.99,"value":339025.8,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option granted February 05, 2016 and vested monthly over four years."}],"balance_after":36764,"derivative":{"exercise_price":35.99,"expiration_date":"2026-02-05","underlying":"Common Stock","underlying_shares":9420},"source":{"system":"sec-edgar","filing":"0001209191-18-057772","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057772/doc4.xml","form_type":"4"}},{"id":3770916,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2018-11-08T22:04:06.000Z","date":"2018-11-07","kind":"sale","acquired":false,"shares":15046,"price":110.2628,"value":1659014.0888,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.08 to $110.90. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":135997,"source":{"system":"sec-edgar","filing":"0001209191-18-057772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057772/doc4.xml","form_type":"4"}},{"id":3770915,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2018-11-08T22:04:06.000Z","date":"2018-11-07","kind":"exercise","acquired":true,"shares":15046,"price":8.66,"value":130298.36,"ownership":{"direct":true},"balance_after":151043,"source":{"system":"sec-edgar","filing":"0001209191-18-057772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057772/doc4.xml","form_type":"4"}},{"id":3770914,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2018-11-08T22:04:06.000Z","date":"2018-11-07","kind":"sale","acquired":false,"shares":9122,"price":110.0316,"value":1003708.2552,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.08. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":135997,"source":{"system":"sec-edgar","filing":"0001209191-18-057772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057772/doc4.xml","form_type":"4"}},{"id":3770913,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2018-11-08T22:04:06.000Z","date":"2018-11-07","kind":"exercise","acquired":true,"shares":9122,"price":5.76,"value":52542.72,"ownership":{"direct":true},"balance_after":145119,"source":{"system":"sec-edgar","filing":"0001209191-18-057772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057772/doc4.xml","form_type":"4"}},{"id":3770912,"issuer":{"id":2655,"kind":"organization","name":"NEUROCRINE BIOSCIENCES INC","symbol":"NBIX"},"owners":[{"id":140839,"kind":"person","name":"Bozigian Haig P.","position":1,"cik":"0001423837","reported_name":"Bozigian Haig P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2018-11-08T22:04:06.000Z","date":"2018-11-07","kind":"sale","acquired":false,"shares":5231,"price":110,"value":575410.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan."}],"balance_after":135997,"source":{"system":"sec-edgar","filing":"0001209191-18-057772","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/914475/000120919118057772/doc4.xml","form_type":"4"}}],"next_cursor":"2018-11-08T22:04:06.000000Z,3770912"}